Carl Dambkowski

CMO Carl Dambkowski sold 26.4K APGE shares at $132.60 (via 10b5-1 plan); stock now at $132.69, up 63.5% in 30 days.

Carl Dambkowski sold 26,400 shares for $3,500,640.00 under a pre-arranged 10b5-1 trading plan adopted on 2025-09-22, reducing his holdings by 12.8% to 179,248 shares. The sale occurred at $132.60, within 0.4% of the 52-week high of $133.16, and the stock has since traded slightly higher at $132.69. His prior five trades at APGE show mixed outcomes—four consecutive sells on 2026-01-07 each posted negative 30-day returns (-21.3%, -19.3%, -20.1%, -22.3%) though longer-term 90-day returns were generally positive—suggesting execution context specific to this ticker differs from his broader cross-ticker track record (14 prior sells with +11.8% avg 30-day return). The company reported a full fiscal year net income of $-74,111,000.00, operating at a loss, which frames the sale against deteriorating fundamentals rather than discretionary conviction-driven activity.

Director Carl Dambkowski sold 35,000 ORKA shares ($2.5M) via 10b5-1 plan; retains 38,743 shares post-sale.

Director Carl Dambkowski executed 2 separate sales totaling 35,000 shares for $2,454,382.15 on 2026-06-11 and 2026-06-12 at an average price of $70.13, reducing his stake by approximately 47.5%. The transaction is part of a pre-arranged 10b5-1 trading plan, meaning it is scheduled rather than discretionary. Oruka Therapeutics posted $0.00 revenue in its latest quarter with a net loss of $-31,820,000.00 and was unprofitable over its most recent full fiscal year. The current stock price of $69.89 is -23.2% from the 52-week high of $91.00, though the 30-day change shows +10.6% and the 90-day change shows +74.7%, indicating recent price recovery from earlier lows.

Director Carl Dambkowski sold 105,000 shares for $6.2M via 10b5-1 plan; stock down 13.0% in 30 days.

Carl Dambkowski, Director at Oruka Therapeutics, executed three separate sales totaling 105,000 shares (105.0K shares) for $6,191,366.32 ($6.2M) at a blended average price of $58.97 on 2026-05-21, reducing his holdings by 58.7% from 178,743 to 73,743 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The stock has declined 13.0% over the prior 30 days and trades at $60.61, down 33.4% from its 52-week high of $91.00, in a context where the company generated zero revenue in its latest quarter and posted a net loss of $31,820,000 ($-31.8M). Investors should note that while the director's cross-ticker track record shows an average 90-day return of +13.4% following prior sells, that success pattern reflects other holdings and does not address directional conviction at this ticker in particular.

CMO Carl Dambkowski sells 18.7K shares (18,700 shares) for $1.5M ($1,455,613.06) across 4 transactions on 2026-01-07

Carl Dambkowski, Chief Medical Officer, executed 4 separate sales totaling 18,700 shares for $1,455,613.06 on 2026-01-07, reducing his holdings by 8.1% from 231,223 to 212,523 shares post-transaction. The sales occurred at prices between $77.13–$80.06, with a blended average of $77.84, near the current price of $77.99 and within 1.2% of the 52-week high of $78.95. Apogee Therapeutics reported a net loss of $-65,021,000.00 over its most recent full fiscal year, marking the company as unprofitable. While Dambkowski's cross-ticker track record shows a positive average 30-day return of +31.6% following his prior 5 sells, his APGE-specific prior trades show mixed near-term outcomes (ranging +1.0% to +43.1% at 30-day horizon) with no measurable longer-term results yet available to assess execution timing at this ticker.

CMO Dambkowski sold 10,900 shares (10.9K) of APGE at $75.00 on 2025-12-04; stock now at $76.75.

Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold 10,900 shares at $75.00, reducing his holdings by 3.9%. The stock currently trades at $76.75, just below its 52-week high of $76.75, with strong recent momentum: +38.4% over 30 days and +102.7% over 90 days. His prior four sales at APGE on 2025-11-05 showed 30-day returns ranging from 35.8% to 43.1%, suggesting a pattern of selling into strength. However, the company posted $-65.0M in net income over its most recent full fiscal year, underscoring that this sale occurs against an unprofitable operating backdrop. The timing and scale of this sale merit attention given the company's fundamental challenges and the insider's consistent sales activity.

CMO Carl Dambkowski sold 10,785 shares at avg $55.07 for $593,902.84 on 2025-11-05

On 2025-11-05, Dambkowski executed 4 separate sales totaling 10,785 shares for $593,902.84, representing a 3.7% reduction in his holdings. The sales occurred at prices ranging from $53.62 to $56.51, with a blended average of $55.07, executing near the current price of $54.71 and well above the 52-week low of $28.79. The filing occurs within a context of significant recent stock appreciation: the company has risen 54.6% over the past 90 days and 15.8% over the past 30 days, positioning the stock near its 52-week high of $61.12. However, this comes against deteriorating fundamentals: Apogee Therapeutics reported net income of -$66,096,000.00 for its most recent fiscal year, indicating the company remains substantially unprofitable despite the equity market momentum. The magnitude of the sale ($593,902.84) and the reduction in an already substantial position (282,008 shares remaining) merit investor scrutiny given the widening disconnect between market enthusiasm and underlying business performance.